Abstract
The low regeneration potential of the central nervous system (CNS) represents a challenge for the development of new therapeutic strategies for neurodegenerative diseases, including spinocerebellar ataxias. Spinocerebellar ataxia type 3 (SCA3)—or Machado–Joseph disease (MJD)—is the most common dominant ataxia, being mainly characterized by motor deficits; however, SCA3/MJD has a complex and heterogeneous pathophysiology, involving many CNS brain regions, contributing to the lack of effective therapies. Mesenchymal stem cells (MSCs) have been proposed as a potential therapeutic tool for CNS disorders. Beyond their differentiation potential, MSCs secrete a broad range of neuroregulatory factors that can promote relevant neuroprotective and immunomodulatory actions in different pathophysiological contexts. The objective of this work was to study the effects of (1) human MSC transplantation and (2) human MSC secretome (CM) administration on disease progression in vivo, using the CMVMJD135 mouse model of SCA3/MJD. Our results showed that a single CM administration was more beneficial than MSC transplantation—particularly in the cerebellum and basal ganglia—while no motor improvement was observed when these cell-based therapeutic approaches were applied in the spinal cord. However, the effects observed were mild and transient, suggesting that continuous or repeated administration would be needed, which should be further tested.
Highlights
We first investigated the potential of conditioned medium (CM) to promote amelioration of the motor decline and loss of muscular strength observed in a Spinocerebellar ataxia type 3 (SCA3)/Machado–Joseph disease (MJD) mouse model—the CMVMJD135 transgenic mouse, which shows a progressive SCA3/MJD-like phenotype that closely mimics human disease [7]
Because it has been suggested that the Human MSCs (hMSCs) secretome per se may exert relevant neuroprotective actions in different neuropathological contexts [42,59,60], we tested the potential of CM to mitigate the neurological phenotype of the CMVMJD135 mice
We evaluated the therapeutic potential of hMSC transplantation or CM administration to different central nervous system (CNS) regions known to be affected in SCA3/MJD: the cerebellum, the striatum/SN, and the spinal cord
Summary
The burden of neurodegenerative diseases is growing with the aging of the population. Degeneration of neurons in the cerebellum, brainstem, and spinocerebellar tracts causes ataxia (reviewed in [1]). Many different types of inherited ataxia have been defined [2], including spinocerebellar ataxias (SCAs). Among SCAs, autosomal-dominant inherited polyglutamine (polyQ) diseases are the most frequent, of which SCA3/Machado–
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
